Facial recognition of heroin vaccine opiates: Type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine

Vaccine

Volumn 32, Issue 13, 2014, Pages 1473-1479

  Matyas, Gary R ^a   Rice, Kenner C ^b   Cheng, Kejun ^b   Li, Fuying ^b   Antoline, Joshua F G ^b   Iyer, Malliga R ^b   Jacobson, Arthur E ^b   Mayorov, Alexander V ^a,c   Beck, Zoltan ^a,c   Torres, Oscar B ^a,c   Alving, Carl R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

6 Acetylmorphine; Haptens; Heroin; Liposomes; Monophosphoryl lipid A; Morphine; Tetanus toxoid; Type 1 and type 2 cross reactivity; Vaccines to drugs of abuse

Indexed keywords

DIAMORPHINE; HEROIN VACCINE; MORPHINE; MORPHINE 6 ACETATE; OPIATE ANTAGONIST; PHOSPHORYL LIPID A; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANTIGEN ANTIBODY REACTION; ANTINOCICEPTION; ARTICLE; BINDING SITE; CONTROLLED STUDY; CROSS REACTION; DRUG CONJUGATION; DRUG STRUCTURE; DRUG SYNTHESIS; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL;

6-ACETYLMORPHINE; HAPTENS; HEROIN; LIPOSOMES; MONOPHOSPHORYL LIPID A; MORPHINE; TETANUS TOXOID; TYPE 1 AND TYPE 2 CROSS-REACTIVITY; VACCINES TO DRUGS OF ABUSE;

ANIMALS; ANTIBODY SPECIFICITY; CROSS REACTIONS; FEMALE; HAPTENS; HEROIN; HEROIN DEPENDENCE; LIPID A; LIPOSOMES; MICE; MICE, INBRED BALB C; MORPHINE; MORPHINE DERIVATIVES; NOCICEPTION; VACCINES;

EID: 84896736754     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.028     Document Type: Article

References (19)

1. Anton B., Salazar A., Flores A., Matus M., Marin R., Hernandez J.A., et al. Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum Vaccines 2009, 5(4):214-229.
2. Kinsey B.M., Jackson D.C., Orson F.M. Vaccines against drug abuse. Anti-drug vaccines to treat substance abuse. Immunol Cell Biol 2009, 87(4):309-314.
3. Shen X.Y., Orson F.M., Kosten T.R. Vaccines against drug abuse. Clin Pharmacol Ther 2012, 91(1):60-70.
4. Stowe G.N., Schlosburg J.E., Vendruscolo L.F., Edwards S., Misra K.K., Schulteis G., et al. Developing a vaccine against multiple psychoactive targets: a case study of heroin. Neurol Disord Drug Targets 2011, 10(8):865-875.
5. Turner M. Antibodies. Immunology 2011, 65-85. Mosby, Edinburgh. 6th ed. I. Roitt, J. Brostoff, D. Male (Eds.).
6. Berzofsky J.A., Schechter A.N. The concepts of crossreactivity and specificity in immunology. Mol Immunol 1981, 18(8):751-763.
7. Berzofsky J.A., Berkower I.A. Antigen-antibody interactions and monoclonal antibodies. Fundamental immunology 2013, 183-214. Lippincott Williams & Wilkins, Philadelphia, PA. 7th ed. W.E. Paul (Ed.).
8. Berzofsky J.A., Berkower I.A. Immunogenicity and antigen structure. Fundamental immunology 2013, 539-582. Lippincott Williams & Wilkins, Philadelphia, PA. 7th ed. W.E. Paul (Ed.).
9. Stowe G.N., Vendruscolo L.F., Edwards S., Schlosburg J.E., Misra K.K., Schulteis G., et al. A vaccine strategy that induces protective immunity against heroin. J Med Chem 2011, 54(14):5195-5204.
10. Schlosburg J.E., Vendruscolo L.F., Bremer P.T., Lockner J.W., Wade C.L., Nunes A.A., et al. Dynamic vaccine blocks relapse to compulsive intake of heroin. PNAS 2013, 110(22):9036-9041.
11. Bremer P.T., Janda K.D. Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance. J Med Chem 2012, 55(23):10776-10780.
12. Alving C.R., Rao M., Steers N.J., Matyas G.R., Mayorov A.V. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. Expert Rev Vaccines 2012, 11(6):733-744.
13. Matyas G.R., Mayorov A.V., Rice K.C., Jacobson A.E., Cheng K., Iyer M.R., et al. Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine 2013, 31:2804-2810.
14. Matyas G.R., Muderhwa J.M., Alving C.R. Oil-in-water liposomal emulsions for vaccine delivery. Methods Enzymol 2003, 373:34-50.
15. Bannon A.W., Malmberg A.B. Models of nociception: hot plate, tail-flick, and formalin tests. Curr Protoc Neurosci 2007, (Suppl 41):8.9.1-8.9.16.
16. Zhang H., Wang S., Fang G. Applications and recent developments of multi-analyte simultaneous analysis by enzyme-linked immunosorbent assays. J Immunol Methods 2011, 368(1-2):1-23.
17. Anton B., Leff P. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 2006, 24(16):3232-3240.
18. Kosten T.A., Shen X.Y., O'Malley P.W., Kinsey B.M., Lykissa E.D., Orson F.M., et al. A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats. Prog Neuropsychopharmacol Biol Psychiatry 2013, 45:223-229.
19. Raleigh M.D., Pravetoni M., Harris A.C., Birnbaum A.K., Pentel P.R. Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. J Pharmacol Exp Ther 2013 Feb, 344(2):397-406.